Climb Bio (CLYM) Competitors $1.26 0.00 (0.00%) As of 04/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock CLYM vs. AMLX, ERAS, ALLO, TRDA, TPST, MREO, TKNO, PHAT, HRTX, and ORKAShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Amylyx Pharmaceuticals (AMLX), Erasca (ERAS), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Tempest Therapeutics (TPST), Mereo BioPharma Group (MREO), Alpha Teknova (TKNO), Phathom Pharmaceuticals (PHAT), Heron Therapeutics (HRTX), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Amylyx Pharmaceuticals Erasca Allogene Therapeutics Entrada Therapeutics Tempest Therapeutics Mereo BioPharma Group Alpha Teknova Phathom Pharmaceuticals Heron Therapeutics Oruka Therapeutics Amylyx Pharmaceuticals (NASDAQ:AMLX) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Does the MarketBeat Community believe in AMLX or CLYM? Amylyx Pharmaceuticals received 33 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 67.31% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmylyx PharmaceuticalsOutperform Votes3567.31% Underperform Votes1732.69% Climb BioOutperform Votes2100.00% Underperform VotesNo Votes Is AMLX or CLYM more profitable? Amylyx Pharmaceuticals' return on equity of -36.97% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -36.97% -29.61% Climb Bio N/A -42.21%-41.39% Which has higher earnings and valuation, AMLX or CLYM? Amylyx Pharmaceuticals has higher revenue and earnings than Climb Bio. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M4.04$49.27M-$4.44-0.90Climb BioN/AN/A-$35.12M-$2.13-0.59 Does the media refer more to AMLX or CLYM? In the previous week, Amylyx Pharmaceuticals had 9 more articles in the media than Climb Bio. MarketBeat recorded 9 mentions for Amylyx Pharmaceuticals and 0 mentions for Climb Bio. Amylyx Pharmaceuticals' average media sentiment score of 0.98 beat Climb Bio's score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Amylyx Pharmaceuticals Positive Climb Bio Neutral Do insiders & institutionals hold more shares of AMLX or CLYM? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 3.2% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, AMLX or CLYM? Amylyx Pharmaceuticals has a beta of -0.53, suggesting that its share price is 153% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Do analysts prefer AMLX or CLYM? Amylyx Pharmaceuticals presently has a consensus price target of $8.00, suggesting a potential upside of 101.01%. Climb Bio has a consensus price target of $10.00, suggesting a potential upside of 693.65%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryAmylyx Pharmaceuticals beats Climb Bio on 10 of the 16 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.02M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.45%4.31%P/E Ratio-0.596.9521.9417.82Price / SalesN/A231.00380.9497.68Price / CashN/A65.6738.2634.64Price / Book0.325.936.453.98Net Income-$35.12M$143.22M$3.22B$247.81M7 Day Performance-1.56%4.28%5.85%3.19%1 Month Performance-1.56%-13.11%-9.55%-7.70%1 Year PerformanceN/A-8.51%11.83%1.49% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio2.436 of 5 stars$1.26flat$10.00+693.7%N/A$85.02MN/A-0.599Gap DownAMLXAmylyx Pharmaceuticals3.108 of 5 stars$3.40-2.6%$8.00+135.3%+112.8%$299.48M$87.37M-0.88200Analyst RevisionGap DownERASErasca3.3615 of 5 stars$1.06-11.7%$4.83+358.1%-35.2%$298.85MN/A-1.27120Short Interest ↓ALLOAllogene Therapeutics3.0395 of 5 stars$1.40-1.8%$9.29+565.9%-58.2%$298.74M$22,000.00-0.88310News CoverageTRDAEntrada Therapeutics2.8343 of 5 stars$7.80-5.7%$25.67+229.1%-33.1%$290.61M$210.78M4.86110Positive NewsHigh Trading VolumeTPSTTempest Therapeutics2.4031 of 5 stars$6.09-14.9%$10.00+64.3%-81.9%$281.54MN/A-3.9920MREOMereo BioPharma Group2.0288 of 5 stars$1.80-5.3%$7.71+328.6%-12.9%$276.94M$1M-29.7540TKNOAlpha Teknova1.5011 of 5 stars$5.15-10.2%$8.50+65.1%+188.0%$273.70M$37.75M-6.92240Positive NewsGap UpPHATPhathom Pharmaceuticals3.5599 of 5 stars$3.93-11.3%$22.17+464.0%-55.1%$271.31M$55.25M-0.68110Analyst ForecastNews CoverageHRTXHeron Therapeutics3.5401 of 5 stars$1.79-5.0%$5.67+217.3%-30.3%$270.84M$144.29M-9.88300Positive NewsORKAOruka Therapeutics3.0757 of 5 stars$7.31+2.0%$39.86+445.2%N/A$270.70MN/A-1.15N/AUpcoming EarningsNews Coverage Related Companies and Tools Related Companies Amylyx Pharmaceuticals Competitors Erasca Competitors Allogene Therapeutics Competitors Entrada Therapeutics Competitors Tempest Therapeutics Competitors Mereo BioPharma Group Competitors Alpha Teknova Competitors Phathom Pharmaceuticals Competitors Heron Therapeutics Competitors Oruka Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
